Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company focuses on macrophage reprogramming immunotherapy aimed at treating sepsis, COVID-19, and solid tumors. An on-demand presentation will be accessible starting 7:00 AM Eastern Time on September 13, 2021, through the provided link. Enlivex is advancing Allocetra™, a novel therapy designed to restore macrophage homeostasis, crucial for immune system balance.

Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that Company management will present a corporate overview at the H.C. Wainwright 23^rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021 and can be accessed through the following link: https://journey.ct.events/view/05f06487-cd1d-4dbb-8088-fb6559861045.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra^TM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information visit http://www.enlivex.com. 

ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com

FAQ

When is Enlivex presenting at the H.C. Wainwright 23rd Annual Global Investment Conference?

Enlivex will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What is the focus of Enlivex's presentation at the conference?

Enlivex's presentation will focus on its clinical-stage macrophage reprogramming immunotherapy aimed at sepsis, COVID-19, and solid tumors.

How can I access Enlivex's presentation during the conference?

The presentation will be available on-demand starting at 7:00 AM Eastern Time on September 13, 2021, through the conference link.

What is Allocetra™ developed by Enlivex?

Allocetra™ is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state to balance the immune system.

What types of diseases does Enlivex aim to target with its therapies?

Enlivex targets diseases such as sepsis, COVID-19, and solid tumors through its macrophage reprogramming technology.